Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.2%

4 terminated out of 77 trials

Success Rate

87.5%

+0.9% vs benchmark

Late-Stage Pipeline

13%

10 trials in Phase 3/4

Results Transparency

29%

8 of 28 completed with results

Key Signals

8 with results88% success

Data Visualizations

Phase Distribution

62Total
Not Applicable (21)
P 1 (7)
P 2 (24)
P 3 (10)

Trial Status

Completed28
Recruiting21
Active Not Recruiting11
Unknown8
Withdrawn5
Terminated4

Trial Success Rate

87.5%

Benchmark: 86.6%

Based on 28 completed trials

Clinical Trials (77)

Showing 20 of 20 trials
NCT04609280Phase 2Active Not Recruiting

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)

NCT03416153Phase 2CompletedPrimary

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

NCT05388773Phase 2RecruitingPrimary

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

NCT05787639Phase 2Active Not RecruitingPrimary

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT04667585Not ApplicableActive Not RecruitingPrimary

Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT06563362Phase 2RecruitingPrimary

Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma

NCT05800574Phase 2RecruitingPrimary

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

NCT06234748Phase 2Active Not RecruitingPrimary

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

NCT06997068Phase 2Recruiting

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

NCT06706401Phase 3RecruitingPrimary

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

NCT05307939Phase 2Recruiting

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT06554158Not ApplicableRecruitingPrimary

De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers

NCT03174275Phase 2Active Not Recruiting

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

NCT07063212Phase 2Recruiting

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

NCT07033091Not ApplicableRecruitingPrimary

Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening

NCT03082534Phase 2Completed

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

NCT07337122Completed

Collagen Matrix in Oral Cancer Surgery

NCT04124198Not ApplicableActive Not RecruitingPrimary

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Scroll to load more

Research Network

Activity Timeline